Susceptibility surveillance among gram-negative bacilli at a cancer center

Kalen Jacobson; Kenneth Rolston; Linda Elting; Barbara LeBlanc; Estella Whimbey; Dan Hsi Ho

doi:10.1159/000007223

Susceptibility surveillance among gram-negative bacilli at a cancer center

Kalen Jacobson, Kenneth Rolston, Linda Elting, Barbara LeBlanc, Estella Whimbey, Dan Hsi Ho

Infectious Diseases, Infection Control, and Employee Health

Research output: Contribution to journal › Article › peer-review

45 Scopus citations

Abstract

We conducted a survey of susceptibility among 758 gram-negative bacilli (GNB; collected from cancer patients over a 3-month period) to commonly used antibiotics. The overall resistance among GNB was least for piperacillin/tazobactam and meropenem (5 and 6%, respectively) followed by cefepime (8%), imipenem (9%), amikacin (12%), ofloxacin (13%), ciprofloxacin, ceftazidime and ticarcillin/clavulanate (14% each), aztreonam (18%) and tobramycin (24%). In comparison to data on antibiotic resistance to ceftazidime, imipenem, ciprofloxacin and aztreonam in similar studies in 1985 and 1994, resistance has significantly increased to all four antibiotic classes. Based on our current study, meropenem, cefepime, imipenem and piperacillin/tazobactam would be the most appropriate choices in our institution for empiric therapy of GNB infections in febrile neutropenic patients.

Original language	English (US)
Pages (from-to)	325-334
Number of pages	10
Journal	Chemotherapy
Volume	45
Issue number	5
DOIs	https://doi.org/10.1159/000007223
State	Published - 1999

Keywords

Gram-negative bacilli
Resistance, antimicrobial
Resistance, increasing

ASJC Scopus subject areas

Oncology
Pharmacology
Drug Discovery
Pharmacology (medical)
Infectious Diseases

Access to Document

10.1159/000007223

Cite this

@article{94e3d82c80a6465dbef3d76c9e78c07a,

title = "Susceptibility surveillance among gram-negative bacilli at a cancer center",

abstract = "We conducted a survey of susceptibility among 758 gram-negative bacilli (GNB; collected from cancer patients over a 3-month period) to commonly used antibiotics. The overall resistance among GNB was least for piperacillin/tazobactam and meropenem (5 and 6%, respectively) followed by cefepime (8%), imipenem (9%), amikacin (12%), ofloxacin (13%), ciprofloxacin, ceftazidime and ticarcillin/clavulanate (14% each), aztreonam (18%) and tobramycin (24%). In comparison to data on antibiotic resistance to ceftazidime, imipenem, ciprofloxacin and aztreonam in similar studies in 1985 and 1994, resistance has significantly increased to all four antibiotic classes. Based on our current study, meropenem, cefepime, imipenem and piperacillin/tazobactam would be the most appropriate choices in our institution for empiric therapy of GNB infections in febrile neutropenic patients.",

keywords = "Gram-negative bacilli, Resistance, antimicrobial, Resistance, increasing",

author = "Kalen Jacobson and Kenneth Rolston and Linda Elting and Barbara LeBlanc and Estella Whimbey and Ho, {Dan Hsi}",

year = "1999",

doi = "10.1159/000007223",

language = "English (US)",

volume = "45",

pages = "325--334",

journal = "Chemotherapy",

issn = "0009-3157",

publisher = "S. Karger AG",

number = "5",

}

TY - JOUR

T1 - Susceptibility surveillance among gram-negative bacilli at a cancer center

AU - Jacobson, Kalen

AU - Rolston, Kenneth

AU - Elting, Linda

AU - LeBlanc, Barbara

AU - Whimbey, Estella

AU - Ho, Dan Hsi

PY - 1999

Y1 - 1999

N2 - We conducted a survey of susceptibility among 758 gram-negative bacilli (GNB; collected from cancer patients over a 3-month period) to commonly used antibiotics. The overall resistance among GNB was least for piperacillin/tazobactam and meropenem (5 and 6%, respectively) followed by cefepime (8%), imipenem (9%), amikacin (12%), ofloxacin (13%), ciprofloxacin, ceftazidime and ticarcillin/clavulanate (14% each), aztreonam (18%) and tobramycin (24%). In comparison to data on antibiotic resistance to ceftazidime, imipenem, ciprofloxacin and aztreonam in similar studies in 1985 and 1994, resistance has significantly increased to all four antibiotic classes. Based on our current study, meropenem, cefepime, imipenem and piperacillin/tazobactam would be the most appropriate choices in our institution for empiric therapy of GNB infections in febrile neutropenic patients.

AB - We conducted a survey of susceptibility among 758 gram-negative bacilli (GNB; collected from cancer patients over a 3-month period) to commonly used antibiotics. The overall resistance among GNB was least for piperacillin/tazobactam and meropenem (5 and 6%, respectively) followed by cefepime (8%), imipenem (9%), amikacin (12%), ofloxacin (13%), ciprofloxacin, ceftazidime and ticarcillin/clavulanate (14% each), aztreonam (18%) and tobramycin (24%). In comparison to data on antibiotic resistance to ceftazidime, imipenem, ciprofloxacin and aztreonam in similar studies in 1985 and 1994, resistance has significantly increased to all four antibiotic classes. Based on our current study, meropenem, cefepime, imipenem and piperacillin/tazobactam would be the most appropriate choices in our institution for empiric therapy of GNB infections in febrile neutropenic patients.

KW - Gram-negative bacilli

KW - Resistance, antimicrobial

KW - Resistance, increasing

UR - http://www.scopus.com/inward/record.url?scp=0032822405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032822405&partnerID=8YFLogxK

U2 - 10.1159/000007223

DO - 10.1159/000007223

M3 - Article

C2 - 10473920

AN - SCOPUS:0032822405

SN - 0009-3157

VL - 45

SP - 325

EP - 334

JO - Chemotherapy

JF - Chemotherapy

IS - 5

ER -

Susceptibility surveillance among gram-negative bacilli at a cancer center

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this